COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib (RESUNET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02713763
Recruitment Status : Completed
First Posted : March 21, 2016
Last Update Posted : March 4, 2020
Apices Soluciones S.L.
Information provided by (Responsible Party):
Grupo Espanol de Tumores Neuroendocrinos

Brief Summary:

The therapeutic goals in the management of pancreatic neuroendocrine tumors (pNET) are the control of symptoms and tumor growth control in order to improve patient survival.

In recent years, data from two phase III studies with targeted therapies, sunitinib and everolimus, have broadened the possibilities for treatment of patients with neuroendocrine tumors of the pancreas.

Unfortunately, patients progress and development of new active drugs and evaluating the best treatment approach is decisive.

Given the lack of data comparing the activity of different treatment strategies, final decisions are based on medical experience and consensus of experts. In this context, different questions are still unanswered, as which is the best sequence of treatment and if all patients can benefit from all available drugs.

Neuroendocrine pancreatic tumors are highly vascularized tumors in which cells may be dependent on this pathway for growth throughout the entire history of the tumor and in which inhibition of this pathway is crucial. On the other hand, this aspect has not been endorsed by the population of patients with pNET who have previously failed treatment with sunitinib.

In this scenario the investigators will assess retreatment with sunitinib to evaluate the activity of this drug in the context of therapeutic rescue in patients with metastatic pNET.

Condition or disease Intervention/treatment Phase
Pancreatic Neuroendocrine Tumour Metastatic Drug: Sunitinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.
Actual Study Start Date : February 14, 2017
Actual Primary Completion Date : October 23, 2019
Actual Study Completion Date : October 23, 2019

Arm Intervention/treatment
Experimental: Sunitinib
Sunitinib 37.5 mg/day
Drug: Sunitinib
Sunitinib 37.5 mg/day
Other Name: Sutent

Primary Outcome Measures :
  1. 6 months progression free survival [ Time Frame: 6 months ]
    Time form start of treatment to progression disease

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 2 years ]
    Time form start of treatment to death

  2. Progression free survival [ Time Frame: 12 months ]
    Time form start of treatment to progression disease

  3. Response duration [ Time Frame: 12 months ]
    Time from first response to progression disease

  4. Overall response rate [ Time Frame: 12 months ]
    Complete response + partial response

  5. Incidence of Adverse Events [ Time Frame: 12 months ]
    Number of adverse events per patient

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects > 18 years old and able to give their informed consent.
  • Patients diagnosed with Neuroendocrine Tumor of pancreatic origin and histologically confirmed, G1/2 according to the World Health Organization (WHO) classification (Ki67 <20% and/or mitotic count >20 mitoses x 10 HPF).
  • Metastatic disease progression in the 12 months prior to baseline visit documented by CT, MRI or Octreoscan.
  • Progression to prior treatment with sunitinib administered for metastatic disease and have received at least 1 line and no more than 2 lines of subsequent systemic treatment.
  • Measurable disease according to the following criteria RECIST version 1.1
  • No disease that can be treated with surgery, radiotherapy or combined treatment with curative intent.
  • Eastern Cooperative Oncology Group (ECOG) 0-2.
  • Pretreatment with somatostatin analogues, chemotherapy, anti-VEGF (vascular endothelial growth factor) and mTOR (mammalian target of rapamycin) inhibitors prior to participation in the study is allowed.
  • Adequately controlled blood pressure (BP) <150/90 mmHg.
  • Hematologic Function: - Absolute neutrophil count >1500 / microliter (uL) - Platelets >100,000 / uL - Hemoglobin >5.6 mmol / L (9 g / dL)
  • Liver function: total bilirubin < 1.5 x upper limit of normal (ULN), unless unconjugated hyperbilirubinemia or Gilbert syndrome. - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 x ULN (< 5 times in case of liver metastases).
  • Renal function: calculated creatinine clearance according to Cockcroft-Gault > 30 ml / min.
  • Blood coagulation: prothrombin time (PT) or International Normalized Ratio (INR) < 1.2 x ULN.
  • Proteinuria <2+ urine dipstick. If > 2+ proteinuria, urinary protein <1 g / 24 h.
  • Life expectancy> 3 months.
  • Patient able to swallow the study drug and comply with the monitoring requirements of the study. - Women of childbearing potential must present a negative pregnancy test. Women of childbearing potential must agree to use contraception.
  • Men whose partners are women of childbearing potential must use effective contraception.

Exclusion Criteria:

  • Neuroendocrine tumors of pancreatic origin G3 according to WHO classification.
  • Patients who received 3 or more lines of systemic treatment.
  • Major surgery or trauma within 4 weeks prior to the first dose of sunitinib.
  • Radiation therapy or tumor embolization within 2 weeks prior to the first dose of sunitinib.
  • Chemotherapy, immunotherapy, biologic therapy or investigational therapy within the previous 2 weeks or 5 half-lives of the drug last received before the start of the first dose of sunitinib treatment.
  • Prior treatment with high-dose chemotherapy that required hematopoietic rescue.
  • Immunosuppressive therapy or prolonged treatment with corticosteroids concomitantly administered in the previous 3 months.
  • Resolution to grade <2 (CTCAE according V4.03) of all previous related toxicities except alopecia treatments.
  • Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 (according CTCAE V4.03) and/or that is progressing in severity, except alopecia.
  • Treatment with potent inhibitors or inducers of CYP3A4 or known to prolong the QT interval in the previous 7 days.
  • Prior radiotherapy to more than 25% of the bone marrow - Presence of uncontrolled metastatic brain disease, spinal cord compression, meningeal carcinomatosis or leptomeningeal disease.
  • Any gastrointestinal malabsorption disorder or any other condition that, at investigator's criteria, may affect the absorption of sunitinib or increase the risk of bleeding or perforation.
  • Presence of any non-healing wound or ulcer.
  • Grade III/IV diarrhea in the screening period.
  • Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.
  • Clinically significant cardio/cerebrovascular disease in the 6 months prior to treatment.
  • Cardiac arrhythmias (NCI CTCAE version 4.0 grade >2), atrial fibrillation of any grade that requires medical treatment.
  • Corrected QT interval (QTcF) > 180 msec.
  • Active hemoptysis in the past 6 weeks.
  • Evidence of active bleeding or bleeding diathesis.
  • Presence of endobronchial lesions and/or lesions that infiltrate large vessels.
  • Current treatment with acenocoumarol at therapeutic doses.
  • Known HIV infection.
  • Presence of uncontrolled active infection.
  • Pregnant or breastfeeding women.
  • Previous allergic reaction to components structurally similar to sunitinib or any of the excipients.
  • Inability to discontinue any prohibited concomitant medication.
  • Any illness (medical or psychiatric) or reason, in the investigator's opinion, that interferes with the patient's ability to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02713763

Layout table for location information
Hospital Universitario Central de Asturias
Oviedo, Asturias, Spain, 33011
Hospital Universitario Valle de Hebrón
Barcelona, Spain, 08035
Hospital Reina Sofía
Córdoba, Spain, 14004
Hospital Universitario Donostia
Donostia/San Sebastián, Spain, 20014
Hospital Ramón y Cajal
Madrid, Spain, 28034
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Hospital General Universitario J.M. Morales Meseguer
Murcia, Spain, 30008
Complejo Hospitalario Regional Virgen Del Rocío
Sevilla, Spain, 41013
Instituto Valenciano de Oncología
Valencia, Spain, 46009
Sponsors and Collaborators
Grupo Espanol de Tumores Neuroendocrinos
Apices Soluciones S.L.
Layout table for investigator information
Principal Investigator: Enrique Grande MD Anderson Cancer Center MADRID
Layout table for additonal information
Responsible Party: Grupo Espanol de Tumores Neuroendocrinos Identifier: NCT02713763    
Other Study ID Numbers: GETNE-2016-01
2015-005774-37 ( EudraCT Number )
First Posted: March 21, 2016    Key Record Dates
Last Update Posted: March 4, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Grupo Espanol de Tumores Neuroendocrinos:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Adenoma, Islet Cell
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action